Blood clots complicate cancer treatment.  New and more aggressive treatments raise the risk of blood clots in cancer patients.
D020533:Angiogenesis Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000959:Antihypertensive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000068258:Bevacizumab; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D012307:Risk Factors; D020246:Venous Thrombosis / Q000139:chemically induced* / Q000209:etiology
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000959:Antihypertensive Agents; D000068258:Bevacizumab